Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share was 3.2% above ...
Earnings call ResMed reported Q2 FY26 revenue of $1.42B, up 11% YoY (9% in constant currency), with GAAP EPS up 16%. Gross margin expanded 110 bps YoY to 62.3%, driven by supply chain efficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results